In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression
Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally. In 2022, Hamburg emerged as a primary hub
Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract Abstract In October 2022, PROVIREX announced a major
In October 2022, PROVIREX announced a major expansion in Hamburg’s . Abstract In October 2022